BioSpace News Archive

A collaborative team of scientists formed The Long COVID Research Initiative to study and treat those battling the long-term effects of the virus, which include serious mental and physical symptoms.

Sequana Medical NV announces its business highlights and financial results for the six-month period ending 30 June 2022 and its outlook for the remainder of the year and beyond.

Innate Pharma SA, announced that the Company will hold a conference call on Thursday, September 15, 2022, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2022.

Basilea Pharmaceutica Ltd. announced that it has entered into an asset purchase agreement with Nodus Oncology for Basilea’s novel poly glycohydrolase inhibitor discovery program.

Sensorion is pleased to announce Sensorion’s participation, in-person, in the Inner Ear Biology Workshop, taking place on September 10-13, 2022, in Trieste, Italy.

LifeArc announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been acquired by ArcutisBiotherapeutics, Inc., a California-based early commercial stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology.

Alnylam Pharmaceuticals, Inc. announced positive results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy.

Scopio Labs, developer of Full-Field Cell Morphology™ imaging and AI-powered analysis platforms to support laboratory professionals in the detection of cancers, anemia, infections, and other blood-related diseases, announced the launch of the Full-Field Bone Marrow Aspirate™ Application.

AlzeCure Pharma AB announced that the United States Patent Office has issued a patent covering ACD856, which is being developed against Alzheimer’s disease and other disorders with cognitive impairment.

An analysis from AbbVie’s three-year, 28-country MEASURE-AD study revealed that people living with moderate to severe atopic dermatitis who are not receiving systemic therapy had greater clinical, psychosocial and economic burdens compared to those receiving systemic therapy.